KADENSA CAPITAL Ltd Decreases Stake in Tempus AI, Inc. $TEM

KADENSA CAPITAL Ltd lessened its holdings in shares of Tempus AI, Inc. (NASDAQ:TEM) by 4.8% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 288,035 shares of the company’s stock after selling 14,628 shares during the quarter. Tempus AI accounts for about 2.4% of KADENSA CAPITAL Ltd’s investment portfolio, making the stock its 14th largest holding. KADENSA CAPITAL Ltd owned approximately 0.17% of Tempus AI worth $23,247,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in Tempus AI by 22.1% during the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock valued at $762,032,000 after buying an additional 1,706,837 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of Tempus AI by 312.7% in the third quarter. BNP Paribas Financial Markets now owns 1,274,549 shares of the company’s stock worth $102,869,000 after acquiring an additional 965,730 shares in the last quarter. AQR Capital Management LLC purchased a new position in shares of Tempus AI in the 2nd quarter valued at $54,020,000. Clear Street Group Inc. acquired a new position in shares of Tempus AI during the 3rd quarter valued at $57,821,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Tempus AI by 411.4% during the 2nd quarter. Geode Capital Management LLC now owns 649,420 shares of the company’s stock valued at $41,264,000 after acquiring an additional 522,443 shares in the last quarter. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Insider Transactions at Tempus AI

In other news, CEO Eric P. Lefkofsky sold 166,250 shares of Tempus AI stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $63.99, for a total transaction of $10,638,337.50. Following the sale, the chief executive officer directly owned 8,974,783 shares of the company’s stock, valued at approximately $574,296,364.17. The trade was a 1.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Erik Phelps sold 9,464 shares of the business’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $59.43, for a total value of $562,445.52. Following the completion of the transaction, the executive vice president owned 79,816 shares in the company, valued at approximately $4,743,464.88. This trade represents a 10.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 570,143 shares of company stock worth $35,595,055 over the last three months. Insiders own 26.27% of the company’s stock.

Tempus AI Price Performance

Shares of TEM stock opened at $49.98 on Monday. The firm has a fifty day simple moving average of $59.20 and a 200-day simple moving average of $71.69. The company has a market capitalization of $8.93 billion, a PE ratio of -35.45 and a beta of 5.29. Tempus AI, Inc. has a twelve month low of $36.22 and a twelve month high of $104.32. The company has a current ratio of 3.13, a quick ratio of 3.00 and a debt-to-equity ratio of 2.52.

Analysts Set New Price Targets

Several brokerages recently issued reports on TEM. Morgan Stanley lowered their price target on Tempus AI from $85.00 to $70.00 and set an “overweight” rating for the company in a report on Tuesday, March 3rd. Needham & Company LLC restated a “buy” rating and set a $75.00 price objective on shares of Tempus AI in a research note on Wednesday, March 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempus AI in a research report on Thursday, January 22nd. Stifel Nicolaus set a $60.00 target price on Tempus AI in a research note on Wednesday, February 25th. Finally, Mizuho initiated coverage on Tempus AI in a report on Thursday, February 19th. They set an “outperform” rating and a $100.00 target price on the stock. Eight investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $78.62.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.